NASDAQ:IFRX

Inflarx N.v Stock Insider Trading

Healthcare > Biotechnology

Buy IFRX

*Your capital is at risk

$2.06

-0.110 (-5.07%)

At Close: Jun 03, 2026

InflaRx N.V Stock Insider Power

Based on the 42 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 5.19M and sold 0 IFRX shares in the last 42 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 42 transactions)	100.00
● Buy	5.19M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 18, 2026 Buy	Ordinary Shares	Kubler Mark Director	Director	0 Value: $0
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Kubler Mark Director	Director	7 308 Value: $96
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Kubler Mark Director	Director	30 000 Value: $55.8K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Kubler Mark Director	Director	30 000 Value: $71.1K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Kubler Mark Director	Director	30 000 Value: $53.7K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Kubler Mark Director	Director	30 000 Value: $72.3K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Kubler Mark Director	Director	30 000 Value: $35.1K
Mar 18, 2026 Buy	Ordinary Shares	Gibney Anthony S Director	Director	0 Value: $0
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Gibney Anthony S Director	Director	30 000 Value: $55.8K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Gibney Anthony S Director	Director	30 000 Value: $71.1K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Gibney Anthony S Director	Director	30 000 Value: $53.7K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Gibney Anthony S Director	Director	30 000 Value: $72.3K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Gibney Anthony S Director	Director	30 000 Value: $35.1K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Ocarroll Derval See Remarks	Officer	20 000 Value: $48.8K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Ocarroll Derval See Remarks	Officer	25 000 Value: $59.3K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Ocarroll Derval See Remarks	Officer	45 000 Value: $80.6K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Ocarroll Derval See Remarks	Officer	70 000 Value: $168.7K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Ocarroll Derval See Remarks	Officer	70 000 Value: $81.9K
Mar 18, 2026 Buy	Performance Stock Option (Right to Buy)	Ocarroll Derval See Remarks	Officer	21 000 Value: $24.6K
Mar 18, 2026 Buy	Ordinary Shares	Fulpius Nicolas Director	Director	0 Value: $0
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Fulpius Nicolas Director	Director	45 000 Value: $83.7K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Fulpius Nicolas Director	Director	45 000 Value: $106.7K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Fulpius Nicolas Director	Director	45 000 Value: $80.6K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Fulpius Nicolas Director	Director	45 000 Value: $108.5K
Mar 18, 2026 Buy	Stock Option (Right to Buy)	Fulpius Nicolas Director	Director	45 000 Value: $52.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT INFLARX N.V.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III c...

Read Full Profile Here